As Kiran Mazumdar Shaw plans succession, Biocon bets on biosimilars and weight problems medicine for subsequent development wave

As Biocon prepares for a management transition past founder Kiran Mazumdar-Shaw, the Bengaluru-based biopharmaceutical firm says years of funding in biosimilars, insulins and GLP-1 therapies are actually starting to translate into scale, working leverage and profitability.

Mazumdar-Shaw, who not too long ago introduced succession plans naming Claire Mazumdar, her niece, as her successor, mentioned the corporate has accomplished the heavy funding cycle wanted to construct its biosimilars platform and is now positioned to monetise these investments.

“Succession planning is at all times a really essential half to make sure that there’s good enterprise management when it comes to continuity of the imaginative and prescient and the strategic intent,” Mazumdar-Shaw advised Enterprise In the present day, including that she had been grooming Claire for the function for a while. She described her successor as somebody able to “constructing an organization”, “managing threat” and delivering sturdy stakeholder engagement after efficiently constructing Bicara Therapeutics right into a Nasdaq-listed firm valued at over $1 billion.

The management change comes as Biocon consolidates its companies into what it calls “one unified international biopharma platform”, following the mixing of its biosimilars, generics formulations and APIs companies. The corporate says the mixing provides it a stronger steadiness sheet, improved capital allocation and a wider international business footprint.

MUST READ: Biocon will get a successor: Why Kiran Mazumdar-Shaw has chosen Claire Mazumdar

For Mazumdar-Shaw, the timing is linked intently to the chance rising in biosimilars globally. “There are going to be $300 billion price of biologics which can be going to lose patent safety over the subsequent 10 years,” she mentioned. “To compete within the biosimilars enterprise, you want a pipeline, scale when it comes to each R&D and manufacturing, and a really sturdy business engine. Biocon has all of that.”

Mazumdar-Shaw believes Biocon’s early-mover benefit, built-in manufacturing mannequin and business scale place it in a different way from newer entrants counting on outsourcing and in-licensing fashions. She mentioned Biocon now has a 20-product biosimilars pipeline spanning marketed merchandise, near-launch property and development-stage candidates.

Biocon’s biologics enterprise stays the corporate’s largest development engine. The biosimilars phase reported income of Rs 10,431 crore in FY26, up 16% year-on-year, whereas EBITDA for the phase rose 40% on an adjusted foundation to Rs 2,751 crore. The enterprise now contributes greater than 60% of consolidated income.

The corporate mentioned the enterprise benefited from stronger uptake in superior markets, together with the US, alongside latest launches and higher working leverage. Its biosimilars portfolio expanded throughout the 12 months with launches of Bosaya and Aukelso, the Denosumab biosimilars referencing Prolia and Xgeva within the US market.

MUST READ: Biocon bets on international markets as rivals battle India’s semaglutide value battle

Mazumdar-Shaw mentioned the US market itself has developed considerably since Biocon first entered the phase. “Biosimilar adoption is getting higher. There’s larger familiarity and credibility that biosimilars have within the US,” she mentioned, noting that Biocon merchandise are gaining market share throughout oncology, immunology and insulin therapies.

Insulins and GLP-1 therapies are rising as one other strategic development space for the corporate. Biocon has already launched liraglutide in Europe and the US and is making ready for semaglutide launches in rising markets.

“We might be the one firm that has a portfolio of insulins on one aspect and GLP-1s on the opposite,” Mazumdar-Shaw mentioned. “We’re right here to not win a dash, however to win a marathon.”

The corporate believes the mixture of insulin capabilities and GLP-1 manufacturing integration may create a long-term aggressive benefit as weight problems and diabetes therapies develop globally. Biocon drew parallels with earlier strategic bets it made in statins and immunosuppressants, the place it will definitely gained dominant market positions.

Importantly for traders, Biocon says the big capital expenditure cycle is now largely behind it. The corporate has already expanded manufacturing capability throughout biosimilars, insulins, peptides and complicated generics. The main focus now could be on utilisation, margin enlargement and return on capital employed.

MUST READ: Weight-loss jabs like Ozempic, Mounjaro can slim you quick—however docs warn of actual dangers

“There isn’t a extra big-ticket capex to be spent going ahead,” Mazumdar-Shaw mentioned. “That gives us the chance to essentially preserve growing plant utilisation after which generate extra profitability on account of that.”

Biocon has additionally highlighted deleveraging and balance-sheet strengthening as key priorities. Its earnings presentation described FY26 as “a transparent inflection level”, marking the shift from integration and funding to “execution and worth creation”.

Shreehas Tambe, who took cost as CEO and Managing Director of Biocon from April 1, 2026, mentioned the corporate is now transferring from the “Protect” section of its technique to a “Consolidate” section targeted on sustainable development.

The generics enterprise, in the meantime, confirmed enchancment pushed by generic liraglutide launches in Europe and regulatory approvals within the US and Australia. The corporate secured US FDA approval for generic liraglutide protecting each diabetes and weight-management indications throughout the quarter.

Biocon’s CRDMO arm, Syngene Worldwide, posted modest development amid weak spot from a big biologics shopper, although the corporate mentioned the underlying enterprise remained steady. Syngene prolonged its partnership with Bristol Myers Squibb by way of 2035 and expanded its antibody-drug conjugate capabilities throughout the 12 months.

MUST READ: Dr. Reddy’s, Nestlé Well being Science launch diet product for sufferers on weight problems medicine

For FY26, Biocon reported consolidated complete earnings of Rs 17,270 crore, up 14% year-on-year, whereas working income rose 13% to Rs 16,927 crore after adjusting for one-time generic lenalidomide gross sales in FY25. EBITDA stood at Rs 3,798 crore with margins enhancing to 22%, whereas internet revenue earlier than distinctive gadgets rose sharply to Rs 436 crore from Rs 103 crore a 12 months earlier on an adjusted foundation.